Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Cash from Operations (Quarterly): -16.53M for Sept. 30, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -16.53M |
| June 30, 2023 | -15.18M |
| March 31, 2023 | -19.29M |
| December 31, 2022 | -18.39M |
| September 30, 2022 | -23.95M |
| June 30, 2022 | -21.60M |
| March 31, 2022 | -25.24M |
| December 31, 2021 | -16.83M |
| September 30, 2021 | -20.68M |
| June 30, 2021 | -66.57M |
| March 31, 2021 | -18.08M |
| December 31, 2020 | -15.17M |
| Date | Value |
|---|---|
| September 30, 2020 | -13.49M |
| June 30, 2020 | 37.56M |
| March 31, 2020 | -17.52M |
| December 31, 2019 | 33.72M |
| September 30, 2019 | -11.24M |
| June 30, 2019 | -12.95M |
| March 31, 2019 | -12.42M |
| December 31, 2018 | -6.444M |
| September 30, 2018 | -7.102M |
| June 30, 2018 | -6.439M |
| March 31, 2018 | -7.141M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-66.57M
Minimum
Jun 2021
37.56M
Maximum
Jun 2020
-14.52M
Average
-17.18M
Median
Cash from Operations (Quarterly) Benchmarks
| Merck & Co Inc | 3.09B |
| Axonics Inc | -9.236M |
| Johnson & Johnson | 3.657B |
| Boston Scientific Corp | 164.00M |
| Ambrx Biopharma Inc (DELISTED) | -18.88M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.029M |
| Cash from Financing (Quarterly) | 2.032M |
| Free Cash Flow | -69.50M |
| Free Cash Flow Per Share (Quarterly) | -4.210 |
| Free Cash Flow to Equity (Quarterly) | -16.62M |
| Free Cash Flow Yield | -81.57% |